Rize Oncology, Inc. is a genetic medicines company, which engages in the creation of gene editing therapies based on the GeneTether platform. The company was founded by Daren Graham, William J. Garner, and R. Geoffrey Sargent on February 12, 2018 and is headquartered in Kelowna, Canada.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Rize Oncology Inc. market cap is $12.12M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Rize Oncology Inc. 52 week high is $0.16 as of November 18, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Rize Oncology Inc. 52 week low is $0.16 as of November 18, 2026.
Rize Oncology Inc. stock price today is $0.16.
Rize Oncology Inc. stock price yesterday was $0.0004.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Rize Oncology Inc.'s P/E ratio is -11.94.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Rize Oncology Inc. P/B ratio is 551.7241.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Rize Oncology Inc. 50-day moving average is $0.16.